Acarix A/S (ACARIX) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Acarix A/S SEK 0.03, price SEK 0.20, upside -87.4%, quality 33 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Acarix A/S for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range kr 0.1776 – kr 1.37 · fair‑value band kr 0.0170 – kr 0.0255 · the kr 0.2025 price screens above the kr 0.0255 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Acarix A/S in your weekly email
Every Wednesday you see whether Acarix A/S is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to support clinical decision making at the point of care.
Show more
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to support clinical decision making at the point of care. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States. The company was founded in 2009 and is headquartered in Malmö, Sweden.
Stock analysis
Acarix A/S (ACARIX) currently trades at kr 0.2025, while our model-based Fair Value estimate is kr 0.0255, implying the stock looks roughly 694.3% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: kr 0.0170 (bear) to kr 0.0255 (bull), the price of kr 0.2025 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Acarix A/S reported revenue of 7.4M SEK in FY2025 versus 3.8M SEK in FY2021, a compound +18.3%/yr. Reported net income was −48.1M SEK in FY2025.
Key figures
Market cap 298M SEK (≈ $30.0M) · P/S ratio 37.0 · EPS (TTM) kr −0.0400 · Return on equity −88.3% · Return on assets (EBIT) −91.7% · Operating margin −349% · Revenue (TTM) 8.1M SEK · Revenue growth (YoY) +40.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 40% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −87%, ACARIX screens richer than that median.
Fair Value models
Bear kr 0.0170Fair Value kr 0.0255Bull kr 0.0255
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.33/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+18.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.7%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.8%
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,909.3% (2020) → −652.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 361 stocks
Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score35 · Bottom 25%
Fair Value upside−87% · Bottom 25%
Profitability
Return on assets−49% · Bottom 25%
Growth and dividend
Revenue growth40% · Top 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B0.79× · Cheaper than median
P/S (TTM)3.74× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 11
FUTURE (revenue growth)100· sector 31
PAST (return on equity)0· sector 8
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 40
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Acarix A/S Fair Value". https://www.fairvalue-calculator.com/stock/ACARIX
Frequently asked questions
Is Acarix A/S (ACARIX) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 0.0255 versus a price of kr 0.2025, about −87% upside (overvalued).
What is the fair value of ACARIX?
Our model-based fair value for Acarix A/S is kr 0.0255 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 0.2025.
What is the quality score of ACARIX?
Acarix A/S has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Acarix A/S (ACARIX)?
Our model-based price target is the fair value of kr 0.0255 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario kr 0.0170, optimistic scenario kr 0.0255. It is a calculation from audited fundamentals, not an analyst target.
What is the Acarix A/S stock forecast for 2026?
Our models put fair value at kr 0.0255, about −87% upside versus a price of kr 0.2025 (overvalued). Cautious scenario kr 0.0170, optimistic scenario kr 0.0255. The calculation is refreshed regularly with new filings.
What is the revenue of Acarix A/S (ACARIX)?
Acarix A/S reported trailing-twelve-month revenue of about 8.1M SEK (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Acarix A/S (ACARIX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Acarix A/S it is kr 0.0255 per share (as of Sep 24, 2026), against a price of kr 0.2025. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Acarix A/S stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ACARIX trades above its calculated fair value: price kr 0.2025, fair value kr 0.0255, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ACARIX?
No. The price is what the market pays today (kr 0.2025); the fair value is what the company's own numbers justify (kr 0.0255). For Acarix A/S the two are kr 0.1770 per share apart. That gap is exactly why we show both numbers side by side.
How much is Acarix A/S worth?
The market values Acarix A/S at about 298M SEK (market capitalisation, as of Sep 24, 2026). Per share that is kr 0.2025; our models calculate a fair value of kr 0.0255 per share.
What do the bullish and bearish scenarios say about ACARIX?
Our models span a range for Acarix A/S: cautious scenario kr 0.0170, base kr 0.0255, optimistic kr 0.0255 per share (as of Sep 24, 2026, price kr 0.2025). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Acarix A/S (ACARIX)?
Balance-sheet figures for Acarix A/S (as of Sep 24, 2026): return on equity −88.3%. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is ACARIX from its 52-week high?
Acarix A/S trades at kr 0.2025, about 40% below its 52-week high of kr 0.3375 and at the low of kr 0.2020 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.0255 is for.
Which stocks are comparable to Acarix A/S?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Acarix A/S stock attractive at the current price?
The data as of Sep 24, 2026: price kr 0.2025, calculated fair value kr 0.0255 (−87%), Quality Score 33/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ACARIX calculated?
We run Acarix A/S through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.0255, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Acarix A/S itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Acarix A/S (ACARIX)?
The closing price on Sep 23, 2026 was kr 0.2025. Our model-based fair value is kr 0.0255, about −87% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Acarix A/S right now?
The price sits above even our optimistic bull case (kr 0.0255). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Acarix A/S
How large is the market capitalisation of Acarix A/S (ACARIX)?
The market capitalisation of Acarix A/S is 298M SEK (≈ $30.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Acarix A/S (ACARIX)?
The price-to-sales ratio of Acarix A/S is 37.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Acarix A/S (ACARIX)?
Earnings per share at Acarix A/S are kr −0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Acarix A/S (ACARIX)?
The return on equity (ROE) of Acarix A/S is −88.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Acarix A/S (ACARIX)?
On an EBIT basis the return on assets of Acarix A/S is −91.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Acarix A/S (ACARIX)?
The operating margin of Acarix A/S is −349% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Acarix A/S (ACARIX)?
Revenue at Acarix A/S is growing +40.2% versus a year earlier (3y avg +8.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Acarix A/S (ACARIX) generate?
The free cash flow of Acarix A/S is −49.1M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Acarix A/S (ACARIX) hold?
Acarix A/S holds more cash than debt, 18.3M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Acarix A/S in the live analysis
One click puts Acarix A/S on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
